Small Pharmaceuticals
Market Cap
₹9,302 ₹9,302 Cr.
P/E
34.97
PEG
3.18
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- Base case hinges on converting planned HCP and retail reach expansion into sustained domestic demand generation, contributing 67% of incremental revenue, while exports normalize to a 16.6% CAGR from a low base.- Bull case triggers if both domestic demand conversion and export order flows surpass expectations, potentially aided by faster HCP coverage adoption and favorable international product allocation.
- Bear case activates if domestic growth falls below 8% in H1 FY27 or export revenue misses the FY26 ₹200 Cr threshold, requiring downgrade to the bear-case path and a compressed terminal EBITDA margin of 33%.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
1.86
Individual < 2 lac
Individual < 2 lac
6.18 %
Institutions
Institutions
20.46 %
Market cap
Market cap
9,302 Cr
No. of Shareholders
No. of Shareholders
47,511
OPM (%)
OPM (%)
37.16 %
PE
PE
34.97
Prom Holding
Prom Holding
71.27 %
ROCE (%)
ROCE (%)
51.43
ROE (%)
ROE (%)
62.53
Sales
Sales
949 Cr
  • Sanofi Cons. Health
  • Procter&Gamble Healt
  • Suven Life Sciences
Last updated on 28 Jul 2026
  • Sanofi Consumer Healthcare India, demerged Jun 2024 and listed Sep 2024, sells domestic over-the-counter allergy, pain and vitamin brands.
  • Core portfolio carries earnings; four recalled brands back contributing; exports ~10%, up 27% in first half.
  • Raising ad spend to mid-teens, doubling doctor reach, expanding digital and direct retail; margins near 37%; eyeing gastro, laxatives, acquisitions via Opella.
  • Net cash, zero debt; operating cash flow funds ongoing spend.
  • Key allergy brands Allegra, Avil still barred from direct consumer ads; reform would widen market.
  • OTC policy reform No timeline, draft expected in 2026
    would unlock direct ads for Allegra, Avil and aid category building.
  • First full-year audit by Price Waterhouse & Co Feb 2027
    settles auditor opinion and any qualifications versus prior auditor.
  • New categories in gastro, laxatives No timeline
    entry beyond three current categories via Opella global portfolio.
  • Inorganic opportunities Ongoing, no firm timeline
    asset-light acquisitions to expand beyond current portfolio.
  • Brand extensions like Combiflam cream No timeline
    lifts consumer engagement before direct-ad unlock.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
3951
52W Range
High
5394
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

3 Neutral

Neutral for this company

2 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Sanofi Consumer Healthcare India Ltd. Business

Sanofi Consumer Healthcare India was incorporated and domiciled in India on May 10, 2023, having its registered office at Vikhroli East, Mumbai. It is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company also has various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily in India.

Sanofi Cons. Health major competitors are Procter&Gamble Healt, Suven Life Sciences, Medplus Health Serv., Strides Pharma Scien, Bliss GVS Pharma, Viyash Scientific, Symbiotec Pharmalab.
Market Cap of Sanofi Cons. Health is ₹9,331 Crs.
While the median market cap of its peers are ₹8,958 Crs.

Sanofi Cons. Health seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Feb Mar Aug
Investor Presentation Mar Aug
Conference Call Mar
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material